![Survival Outcomes in Real-World Settings After Alternative Pembrolizumab Dosing for NCSLC](https://oncodaily.com/pub/uploads/2024/09/986acce101f74a6eb31c029f31a4f492.jpg)
Photo from nst.com.my
Sep 7, 2024, 05:34
Survival Outcomes in Real-World Settings After Alternative Pembrolizumab Dosing for NCSLC
Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X, about recent paper published in Lung Cancer:
Authors: Geeske Grita, Esmée van Geffen, Ruben Malmberg, Roelof van Leeuwen, Stefan Böhringer, Hans JM Smith, Pepijn Brocken, Job FH Eijsink, Esther Dronkers, Pim Gal, Eva Jaarsma, Regine JHM van Drie-Pierik, Anne MP Eldering-Heldens, AN Machteld Wymenga, Peter GM Mol, Juliëtte Zwaveling, Doranne Hilarius.
”Real-world overall survival after alternative dosing for pembrolizumab in the treatment of NCSLC.
In this RWD involving 1996 patients, low-dose pembrolizumab significantly reduces costs without compromising efficacy.”
Source: Yakup Ergün/X
AN Machteld Wymenga
Anne MP Eldering-Heldens
Bower Hospital
cancer
cancer treatment
Doranne Hilarius
Esmée van Geffen
Esther Dronkers
Eva Jaarsma
Geeske Grita
Hans JM Smith
Job FH Eijsink
Juliëtte Zwaveling
Lung cancer
OncoDaily
Oncology
pembrolizumab
Pepijn Brocken
Peter GM Mol
Pim Gal
Regine JHM van Drie-Pierik
Roelof van Leeuwen
Ruben Malmberg
Stefan Böhringer
Yakup Ergün
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023